EPS for Bio-Techne Corporation (TECH) Expected At $1.07 as of May, 2

April 20, 2018 - By Roy Fason

Bio-Techne Corporation (NASDAQ:TECH) Corporate Logo
Big Money Sentiment decreased to 0.98 in Q4 2017. It has change of 0.23, from 2017Q3’s 1.21. The ratio dived due to Bio-Techne Corporation positioning: 27 sold and 88 reduced. 34 funds amassed positions and 79 increased positions. Investors holded 35.91 million in 2017Q3 but now own 35.53 million shares or 1.06% less.
Leucadia National Corporation accumulated 2,530 shs. Amer Century Companies invested in 420,989 shs or 0.05% of the stock. State Street Corp has 0.01% invested in Bio-Techne Corporation (NASDAQ:TECH) for 1.01 million shs. Voya Invest Management invested in 13,526 shs. National Bank & Trust Of America De has invested 0.01% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Schroder Mgmt Gp holds 0.06% in Bio-Techne Corporation (NASDAQ:TECH) or 271,740 shs. Macquarie Gru reported 192,622 shs or 0.04% of all its holdings. Wealthtrust reported 159 shs. Denver Advsr Ltd Llc holds 0.86% or 132,475 shs. Weaver C Barksdale And Assocs Inc accumulated 0% or 24 shs. Company Bank reported 0.02% stake. New Mexico Educational Retirement Board owns 9,273 shs for 0.05% of their capital. 7,406 are held by Bessemer Grp. Stephens Ar holds 0% or 456 shs in its capital. Tdam Usa has invested 0.17% of its capital in Bio-Techne Corporation (NASDAQ:TECH).

Bio-Techne Corporation had 1 insider sale and 0 insider buys since February 13, 2018. This’s net activity of $680,303.

Bio-Techne Corporation (NASDAQ:TECH) is awaited to report earnings on May, 2 before the open., according to RTT. Analysts predict 20.22 % diference or $1.07 from the $0.89 EPS from 2017. If the current earnings per share of $1.07 is accurate, TECH’s profit could be $40.10 million. After $0.91 EPS report last quarter, Wall Street now predicts 17.58 % EPS growth of Bio-Techne Corporation. TECH hit $152.78 during the last trading session after $0.59 change.Currently Bio-Techne Corporation is uptrending after 45.31% change in last April 20, 2017. TECH has 23,415 shares volume. TECH outperformed the S&P 500 by 33.76%.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

A total of 6 analysts rate Bio-Techne Corporation (NASDAQ:TECH) as follows: 5 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 83% are bullish. (NASDAQ:TECH) has 9 ratings reports on Apr 20, 2018 according to StockzIntelligence. On Monday, October 23 Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) rating. Robert W. Baird has “Buy” rating and $126.0 target. On Thursday, January 18 Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) rating. Robert W. Baird has “Buy” rating and $154.0 target. On Wednesday, February 7 the rating was maintained by Craig Hallum with “Buy”. On Tuesday, October 31 the firm has “Buy” rating given by Robert W. Baird. In Wednesday, February 7 report Stephens maintained the stock with “Hold” rating. In Tuesday, December 5 report Leerink Swann maintained the stock with “Buy” rating. In Thursday, March 1 report Deutsche Bank maintained the stock with “Buy” rating. On Tuesday, February 6 Robert W. Baird maintained the shares of TECH in report with “Buy” rating.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The company has $5.73 billion market cap. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.The P/E ratio is 50.24. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: